top of page
Search

StratifiCare at ICID 2022


Over the weekend, StratifiCare presented our new exciting clinical study results for our flagship StratifiDen®severe Dengue prediction technology at the International Congress on Infectious Diseases (ICID) in Kuala Lumpur, Malaysia. Out of the 283 Dengue patients who participated in the studies, StratifiDen was able to accurately predict the development of Dengue Haemorrhagic Fever (DHF) with 97% sensitivity and 92% specificity. This allows infectious disease clinicians to manage Dengue patients at a personalized level, and ensure that all Dengue patients at risk of developing DHF have access to hospital beds, especially during large Dengue epidemics.


Every year, 96 million people around the world are infected with Dengue clinically, thereby making Dengue one of the World Health Organization’s Top 10 Threats to Global Public Health. Although there are only on average 500,000 cases of DHF reported annually, up to 60% of all Dengue patients (actual proportion varies with geographies) may be hospitalized due to an inefficient severe Dengue prediction methodology. This results in the wastage of limited healthcare resources and hospital beds, and places DHF patients at risk of not receiving the life-saving hospital care they require.


The clinical studies were jointly performed with three of Singapore’s tertiary hospitals (National University Hospital, Tan Tock Seng Hospital, of which Singapore’s National Centre for Infectious Diseases is part of, and Ng Teng Fong General Hospital). Together, these three hospitals provide care to more than 40% of all Dengue patients in Singapore annually.


Organized by the International Society for Infectious Diseases and the Malaysian Society for Infectious Diseases and Chemotherapy, the purpose of ICID is to share international best practices for addressing global challenges caused by infectious diseases.


StratifiCare's vision is to provide insights on the body through proteins so that everyone everywhere can receive the best treatment. Through discussions with infectious disease key opinion leaders at ICID, we strive to work with experts, institutions, and companies who share the same vision to alleviate the burden of Dengue infection in low- and middle-income countries, thereby contributing to sustainable healthcare systems for all.


StratifiCare’s Chief Executive Officer, Dr Anthony Chua (right), and Chief Marketing Officer, Ms Jennifer Lau (left) presenting our new clinical study results at the ICID in Kuala Lumpur, Malaysia.

Comentários


bottom of page